ABM Respiratory Care Closes $14.8M Oversubscribed Series B to Accelerate Commercialization of BiWaze® Clear

ABM呼吸护理公司完成1480万美元超额认购的B轮融资，以加速BiWaze® Clear的商业化进程。

EAGAN, Minn., June 17, 2025-- ABM Respiratory Care (ABMRC), a medical technology company focused on developing and globally commercializing novel airway clearance and ventilation solutions, today announced the successful close of its Series B financing round, raising $14.8 million—well above its $12 million target.

2025年6月17日，明尼苏达州伊根——ABM呼吸护理公司（ABM Respiratory Care，简称ABMRC），一家专注于开发和全球商业化新型气道清除和通气解决方案的医疗技术公司，今天宣布成功完成其B轮融资，筹集了1480万美元，远超其1200万美元的目标。

The oversubscribed round was led by Peter Soderberg, ABMRC's Chairman of the Board and Managing Partner of Worthy Venture Resources, LLC, who more than doubled his investment in the company. The round also included significant participation from Bluwave Capital, LLC, an investment firm focused on the U.S.

这一轮超额认购由ABMRC董事会主席兼Worthy Venture Resources, LLC的管理合伙人彼得·索德伯格领投，他将自己在该公司的投资增加了一倍多。这一轮还包括来自专注于美国市场的投资公司Bluwave Capital, LLC的重大参与。

healthcare sector with one of the Co-founding Partners joining the Board of Directors, alongside other new and existing investors committed to advancing innovation in respiratory care..

医疗保健领域，其中一位共同创始合伙人加入董事会，与其他新老投资者一起致力于推进呼吸系统护理的创新。

'This investment marks a pivotal moment for ABM Respiratory Care as we expand access to our respiratory therapy platform and bring transformative solutions into more homes and hospitals,' said Greg Miller, CEO of ABMRC. 'We're grateful for the support of our new and existing investors who are excited about our vision for intelligent, connected therapies of people struggling to breathe.'.

“这项投资标志着ABM呼吸护理公司的一个关键时刻，因为我们正在扩大我们的呼吸治疗平台的使用范围，并将变革性的解决方案引入更多的家庭和医院，”ABMRC首席执行官格雷格·米勒表示。“我们感谢新老投资者的支持，他们对我们为呼吸困难患者提供智能、互联治疗的愿景感到兴奋。”

'I was motivated to increase my ownership of ABMRC given its impressive execution to-date and the superior performance of its first two devices in treating patients across the continuum of care,' said Peter Soderberg. 'We welcome the opportunity to support the company's next phase of growth as it expands access to our impactful technology to patients worldwide.'.

彼得·索德伯格表示：“鉴于ABMRC迄今为止令人印象深刻的执行能力，以及其前两种设备在治疗各类护理阶段患者中的卓越表现，我决定增加对ABMRC的持股。我们欢迎有机会支持公司下一阶段的增长，因为它将把我们具有影响力的医疗技术带给全球更多患者。”

The funds will be used to accelerate the commercialization of BiWaze® Clear; ABM Respiratory Care's latest airway clearance system designed for both hospital and home use. This includes scaling U.S. sales efforts, investing in clinical research, and enhancing patient engagement and digital health capabilities..

这笔资金将用于加速 BiWaze® Clear 的商业化进程；ABM 呼吸护理公司最新设计的适用于医院和家庭的气道清除系统。这包括扩大美国销售力度、投资临床研究，以及提升患者参与度和数字健康能力。

BiWaze® Clear helps people clear their lungs more efficiently by combining three therapies in one: lung expansion, high-frequency oscillations, and aerosol delivery with an integrated nebulizer. Its compact, battery-operated design and dual-lumen circuit create a portable, closed-loop system that enhances aerosol deposition deep in the lungs, improves mucus clearance, and shortens therapy time—making it easier for patients to use at home or in the hospital..

BiWaze® Clear 通过将三种疗法合为一体来帮助人们更有效地清理肺部：肺扩张、高频振荡以及通过集成雾化器进行的气溶胶输送。其紧凑型电池供电设计和双管路系统构成了一种便携式闭环系统，可增强气溶胶在肺部深处的沉积，改善痰液清除，并缩短治疗时间——使患者在家中或医院内更易于使用。

About ABM Respiratory Care

关于ABM呼吸护理

ABM Respiratory Care is dedicated to advancing patient care by developing intelligent, clinically differentiated, and innovative respiratory care solutions to help people breathe better inside and outside the hospital. Our connected platform is designed to improve respiratory therapy by providing deeper breathing, improved oxygen exchange, reduce aerosol emission exposure, and communication for better disease management for people with compromised respiratory systems, in any care setting around the world.

ABM呼吸护理致力于通过开发智能、临床差异化和创新的呼吸护理解决方案来提升患者护理水平，帮助人们在医院内外更好地呼吸。我们互联的平台旨在通过提供更深的呼吸、改善氧气交换、减少气溶胶排放暴露以及加强沟通来改善呼吸治疗，为世界各地任何护理环境中的呼吸系统受损患者提供更好的疾病管理。